Evaluation of BMDC circulating populations after treatment with PTX or PTX in combination with either G-CSF or AMD3100. Non–tumor-bearing C57Bl/6 mice (n = 4 to 5 mice per group) were treated with PTX, PTX and G-CSF, or PTX and AMD3100. Mice were bled via retro-orbital sinus for the evaluation of (A) viable CEPs; (B) hemangiocytes; and (C) Gr-1⁺/CD11b⁺ cells (MDSCs), using flow cytometry. ***P < .001 from control group, unless indicated otherwise.